CN105188732A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN105188732A
CN105188732A CN201480024106.3A CN201480024106A CN105188732A CN 105188732 A CN105188732 A CN 105188732A CN 201480024106 A CN201480024106 A CN 201480024106A CN 105188732 A CN105188732 A CN 105188732A
Authority
CN
China
Prior art keywords
fgfr1
fgfr1ecd
cancer
cell
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480024106.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·汉布尔顿
M·R·布利姆
M·P·德扬
G·费伦-布雷迪
R·库马尔
L·奥特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ge Lan Element Smith's Gram Lay Intellecture Property (no 2) Co Ltd
Five Prime Therapeutics Inc
Original Assignee
Ge Lan Element Smith's Gram Lay Intellecture Property (no 2) Co Ltd
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Lan Element Smith's Gram Lay Intellecture Property (no 2) Co Ltd, Five Prime Therapeutics Inc filed Critical Ge Lan Element Smith's Gram Lay Intellecture Property (no 2) Co Ltd
Publication of CN105188732A publication Critical patent/CN105188732A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480024106.3A 2013-05-01 2014-04-30 治疗癌症的方法 Pending CN105188732A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361818220P 2013-05-01 2013-05-01
US61/818,220 2013-05-01
US201361831029P 2013-06-04 2013-06-04
US61/831,029 2013-06-04
PCT/US2014/036140 WO2014179448A2 (en) 2013-05-01 2014-04-30 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CN105188732A true CN105188732A (zh) 2015-12-23

Family

ID=50928263

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480024106.3A Pending CN105188732A (zh) 2013-05-01 2014-04-30 治疗癌症的方法

Country Status (13)

Country Link
US (2) US20160067307A1 (enExample)
EP (1) EP2991669A2 (enExample)
JP (1) JP2016526016A (enExample)
KR (1) KR20160003141A (enExample)
CN (1) CN105188732A (enExample)
AU (1) AU2014259956A1 (enExample)
BR (1) BR112015027607A8 (enExample)
CA (1) CA2908391A1 (enExample)
HK (1) HK1213817A1 (enExample)
MX (1) MX2015015115A (enExample)
RU (1) RU2015150233A (enExample)
SG (1) SG11201508878WA (enExample)
WO (1) WO2014179448A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法，组合物和试剂盒

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US10016484B2 (en) 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer
PH12019501393B1 (en) 2013-08-01 2022-09-07 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JP2018524010A (ja) * 2015-07-24 2018-08-30 デバイオファーム インターナショナル エスエイ Ｆｇｆｒ発現とｆｇｆｒ阻害剤に対する感受性
CN108368174B (zh) * 2015-11-23 2023-04-14 戊瑞治疗有限公司 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
PL238516B1 (pl) 2016-06-13 2021-08-30 Univ Wroclawski Sposób otrzymywania modyfikowanego polipeptydu
WO2018195273A1 (en) * 2017-04-19 2018-10-25 The Corporation Of Mercer University Sam-1 protein, composition and methods of use
BR112019023898A2 (pt) 2017-05-16 2020-06-09 Five Prime Therapeutics Inc método para tratamento de câncer gástrico, uso de um anticorpo e composição

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120237511A1 (en) * 2010-12-09 2012-09-20 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US20020081597A1 (en) 2000-03-31 2002-06-27 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
MXPA02011379A (es) 2000-05-19 2003-06-06 Genentech Inc Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb.
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
EP1910542B1 (en) 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1942884A4 (en) * 2005-11-04 2010-01-06 Merck & Co Inc METHOD FOR THE TREATMENT OF CANCER WITH SAHA, CARBOPLATIN AND PACLITAXEL AND OTHER COMBINATION THERAPIES
ES2342646B1 (es) 2008-06-02 2011-04-26 Institut De Recerca Hospital Universitari Vall Hebron Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
US8481038B2 (en) * 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
CN107050426A (zh) * 2010-11-15 2017-08-18 戊瑞治疗有限公司 Fgfr1胞外域组合疗法
US10016484B2 (en) * 2011-11-14 2018-07-10 Five Prime Therapeutics, Inc. Methods of treating lung cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120237511A1 (en) * 2010-12-09 2012-09-20 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
《GENBANK》: "Genbank:CAC20454.1", 《GENBANK》 *
《GENBANK》: "NCBI Reference sequence:NP_056934.2", 《GENBANK》 *
TC HARDING: "Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.", 《SCIENCE TRANSLATIONAL MEDICINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110785184A (zh) * 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法，组合物和试剂盒

Also Published As

Publication number Publication date
BR112015027607A2 (pt) 2017-12-05
RU2015150233A (ru) 2017-06-02
BR112015027607A8 (pt) 2018-01-23
US20160067307A1 (en) 2016-03-10
AU2014259956A1 (en) 2015-11-12
MX2015015115A (es) 2016-06-07
HK1213817A1 (zh) 2016-07-15
EP2991669A2 (en) 2016-03-09
US20180280470A1 (en) 2018-10-04
SG11201508878WA (en) 2015-11-27
CA2908391A1 (en) 2014-11-06
WO2014179448A3 (en) 2014-12-24
KR20160003141A (ko) 2016-01-08
JP2016526016A (ja) 2016-09-01
WO2014179448A2 (en) 2014-11-06

Similar Documents

Publication Publication Date Title
JP6578318B2 (ja) 癌を治療する方法
CN105188732A (zh) 治疗癌症的方法
JP5416221B2 (ja) 癌患者における診断用途のための方法および組成物
JP6095367B2 (ja) 癌治療のための診断方法および組成物
JP2014513930A (ja) Ｈｒ陽性対象における乳がんのバイオマーカーとしてのｆｇｆｒおよびそのリガンド
JP2011527582A (ja) 腫瘍治療のための診断のための方法および組成物
JP2019023193A (ja) がんを治療する方法
WO2012076582A1 (en) Agtr1 as a marker for bevacizumab combination therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213817

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151223

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1213817

Country of ref document: HK